Готові списки джерел за темами / Sarcomatoid subtype

Зміст

Статті в журналах
Дисертації
Частини книг
Тези доповідей конференцій

Добірка наукової літератури з теми "Sarcomatoid subtype"

Автор: Grafiati

Опубліковано: 7 червня 2025

Оновлено: 2 серпня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Sarcomatoid subtype".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Sarcomatoid subtype"

Santoso, Agus, Ngakan Putra, Ungky Setiawan, Artono Isharanto, Dini Erawati, and Hendy Yudhanto. "Sarcomatoid Carcinoma Of The Mediastinal : A Rare Case of Giant Mass Thymic Carcinoma Subtype." Malang Respiratory Journal 3, no. 1 (2021): 133–38. http://dx.doi.org/10.21776/ub.mrj.2021.003.01.4.

Повний текст джерела

Анотація:

Introduction: Sarcomatoid carcinoma is a type of thymus carcinoma that contains partial or complete spindle cells. Incidence of Sarcomatoid Carcinoma 5-10% of all patients with thymic carcinoma. Carcinoma Sarcomatoid is a highly progressive tumor, most patients will die after 3 years of diagnosis despite aggressive multimodality therapy. Case Description: A 47-year-old woman with chest pain, shortness of breath, coughing, weight loss, enlarging lump in the neck and chest was felt for 1 month. Physical and supporting examination showed anterior superior mediastinal tumors and soft mass tissue i

Стилі APA, Harvard, Vancouver, ISO та ін.

Повний текст джерела

Анотація:

Стилі APA, Harvard, Vancouver, ISO та ін.

Pecoraro, Angela, Giuseppe Rosiello, Stefano Luzzago, et al. "Small Renal Masses With Tumor Size 0 to 2 cm: A SEER-Based Study and Validation of NCCN Guidelines." Journal of the National Comprehensive Cancer Network 18, no. 10 (2020): 1340–47. http://dx.doi.org/10.6004/jnccn.2020.7577.

Повний текст джерела

Анотація:

Background: The NCCN Clinical Practice Guidelines in Oncology for Kidney Cancer recommend active surveillance as an option for initial management of T1a 0- to 2-cm renal lesions, in addition to partial nephrectomy, radical nephrectomy, and focal ablation. However, contemporary data regarding the distribution of patient and renal cell carcinoma characteristics within this special patient group are scarce. Methods: Within the SEER database (2002–2016), 13,364 patients with T1aNanyMany 0- to 2-cm renal lesions treated with nephrectomy were identified. Data were tabulated according to histologic s

Стилі APA, Harvard, Vancouver, ISO та ін.

Park, Hyung Kyu. "The Metastasis Pattern of Renal Cell Carcinoma Is Influenced by Histologic Subtype, Grade, and Sarcomatoid Differentiation." Medicina 59, no. 10 (2023): 1845. http://dx.doi.org/10.3390/medicina59101845.

Повний текст джерела

Анотація:

Background and Objectives: Metastasis is a major cause of death in renal cell carcinoma (RCC) patients; therefore, a better understanding of the metastatic process and the ability to predict metastasis in advance is important for treating patients with RCC. This study aimed to investigate whether histological subtypes of RCC and other factors, such as nuclear grade and sarcomatoid differentiation, could predict the probability and location of metastases in patients with RCC. Materials and Methods: Cases of clear-cell, papillary, chromophobe, and sarcomatoid RCC were retrieved and analyzed from

Стилі APA, Harvard, Vancouver, ISO та ін.

Polyakova, A. S., E. A. Sokolov, and D. Yu Pushkar. "Effectiveness of pembrolizumab in therapy of sarcomatoid variant of metastatic urothelial carcinoma. Clinical case." Cancer Urology 20, no. 4 (2025): 104–11. https://doi.org/10.17650/1726-9776-2024-20-4-104-111.

Повний текст джерела

Анотація:

Sarcomatoid variant of urothelial carcinoma is a rare histological subtype: it is diagnosed in 0.1–0.3 % of all neoplasms of the bladder. The standard 1st line therapy for all types of advanced urothelial carcinoma is chemotherapy which does not necessarily allow to achieve the best or complete responses, especially in the presence of sarcomatoid differentiation. High programmed cell death-ligand 1 (PD-L1) expression in this morphological subtype allows to assume better results of immunotherapy compared to chemotherapy. However, a large number of observations is necessary to confirm this hypot

Стилі APA, Harvard, Vancouver, ISO та ін.

Rahman, Syed, David Hesse, Michael Jalfon, Victoria Kong, and Fady Ghali. "Evaluating the therapeutic role of lymph node dissection in variant histology bladder cancer." Journal of Clinical Oncology 43, no. 5_suppl (2025): 749. https://doi.org/10.1200/jco.2025.43.5_suppl.749.

Повний текст джерела

Анотація:

749 Background: Outcome benefit associated with lymph node dissection (LND) at time of radical cystectomy have been suggested in urothelial bladder cancer (BC), but have not been evaluated in variant subtype BC. Our objective was to characterize the impact of LND on survival outcomes across variant subtype BC. Methods: The National Cancer Database was queried for cases of variant histology bladder cancers using International Classification of Disease-O-3 morphologic codes managed with radical cystectomy between 2004 and 2020. Cases were stratified by variant subtype and LND status. Primary out

Стилі APA, Harvard, Vancouver, ISO та ін.

Di Stefano, Iosè, Greta Alì, Anello Marcello Poma, et al. "New Immunohistochemical Markers for Pleural Mesothelioma Subtyping." Diagnostics 13, no. 18 (2023): 2945. http://dx.doi.org/10.3390/diagnostics13182945.

Повний текст джерела

Анотація:

Pleural mesothelioma (PM) comprises three main subtypes: epithelioid, biphasic and sarcomatoid, which have different impacts on prognosis and treatment definition. However, PM subtyping can be complex given the inter- and intra-tumour morphological heterogeneity. We aim to use immunohistochemistry (IHC) to evaluate five markers (Mesothelin, Claudin-15, Complement Factor B, Plasminogen Activator Inhibitor 1 and p21-activated Kinase 4), whose encoding genes have been previously reported as deregulated among PM subtypes. Immunohistochemical expressions were determined in a case series of 73 PMs,

Стилі APA, Harvard, Vancouver, ISO та ін.

Fatima, Syeda, Hafeza Syeda, Naushaba Tazeen, Idrees Afroze, and Mohammed Adil. "Renal cell carcinomas’ hidden challenge: Sarcomatoid differentiation uncovered." Journal of Medical and Allied Sciences 15, no. 1 (2025): 99. https://doi.org/10.5455/jmas.215330.

Повний текст джерела

Анотація:

Renal cell carcinoma (RCC) with sarcomatoid differentiation accounts for 4% of all RCC cases. This aggressive variant is characterized by spindle-shaped tumor cells and carries a high risk of metastasis and poor outcomes. Accurate diagnosis is crucial due to its aggressiveness and the limited treatment options. A 55-year-old male presented to the nephrology department with right lumbar pain, hematuria, and burning micturition. Radiology showed an enlarged right kidney with a hetero-echoic mass (7x5x2cm) across the mid and lower pole. He underwent right nephrectomy followed by histopathological

Стилі APA, Harvard, Vancouver, ISO та ін.

Anusim, Nwabundo, Damilola Gbadebo, Olabisi Afolayan-Oloye, and Ishmael Jaiyesimi. "Durable Remission with Immunotherapy in a Patient with Sarcomatoid Renal Cell Carcinoma." Journal of Kidney Cancer and VHL 8, no. 4 (2021): 38–42. http://dx.doi.org/10.15586/jkcvhl.v8i4.168.

Повний текст джерела

Анотація:

Sarcomatoid differentiation is a rare and aggressive histologic subtype with poor prognosis, seen in several malignancies. In sarcomatoid renal cell carcinoma (RCC), the degree of sarcomatoid differentiation and the stage at presentation determines the prognosis. Despite resection, chemotherapy and targeted therapy response is modest, with relapse usually occurring within a few months. We present a case of a gentleman with sarcomatoid RCC managed with pembrolizumab, who has had no evidence of recurrence for over 4 years since the last dose of immunotherapy. RCCs with sarcomatoid differentiatio

Стилі APA, Harvard, Vancouver, ISO та ін.

Jeong, Han-Sin, Young-Ik Son, Young-Hyeh Ko, and Sang Yoon Kim. "Sarcomatoid salivary duct carcinoma of the larynx." Journal of Laryngology & Otology 120, no. 2 (2005): 154–57. http://dx.doi.org/10.1017/s0022215105003518.

Повний текст джерела

Анотація:

The sarcomatoid variant is a rare subtype of salivary duct carcinoma that comprises epithelial and sarcomatoid components. The authors present the first reported case of sarcomatoid salivary duct carcinoma occurring in the larynx, which was successfully treated by partial laryngectomy with ipsilateral neck dissection, with no evidence of recurrence after five years.Microscopic analysis revealed a composite epithelial and sarcomatoid tumour. The epithelial component was characterized by papillary proliferation of glandular and ductal structures lined with multilayered epithelial tumour cells. T

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Sarcomatoid subtype"

Fontugne, Jacqueline. "Basal/Squamous Subtype of Bladder Cancer : Mechanisms of Progression, Transcriptional Regulators and New Therapeutic Strategies A Consensus Molecular Classification of Muscle-invasive Bladder Cancer Gene Expression Dynamics During Progression to Basal/Squamous Bladder Cancer in the BBN Mouse Model Reveals a Switch From EGFR to FGFR1 Dependency in Sarcomatoid Tumors Enhancer Profiling of Bladder Cancer Reveals a Candidate Basal/Squamous-Specific Core Regulatory Circuitry Tertiary Lymphoid Structures Marker CXCL13 Is Associated With 1 Better Survival for 2 Patients With Advanced-Stage Bladder Cancer Treated With Immunotherapy." Thesis, université Paris-Saclay, 2020. http://www.theses.fr/2020UPASL030.

Повний текст джерела

Анотація:

Le cancer de la vessie est de mauvais pronostic au stade infiltrant le muscle (TVIM). Les TVIM de sous-type basal/squameux (Ba/Sq) peuvent évoluer vers le variant sarcomatoïde et sont de très mauvais pronostic.Les mécanismes de progression des tumeurs non invasives vers une TVIM basale sont difficiles à étudier chez l’homme du fait de son caractère agressif. Dans une première partie, nous avons donc utilisé un modèle murin carcinogène-induit de TVIM Ba/Sq pour étudier l’évolution de l’expression génique depuis les stades pré-invasifs menant au TVIM Ba/Sq et au variant sarcomatoïde. Nous avons

Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "Sarcomatoid subtype"

Lee, Christine U., and James F. Glockner. "Case 13.8." In Mayo Clinic Body MRI Case Review, edited by Christine U. Lee and James F. Glockner. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199915705.003.0332.

Повний текст джерела

Анотація:

62-year-old man with shortness of breath and an abnormal chest CT Axial 3D SPGR postgadolinium images (Figure 13.8.1) demonstrate diffuse thickening and enhancement of the left pleura, with a few minimally enhancing, focal right-sided pleural plaques. Malignant pleural mesothelioma Malignant pleural mesothelioma is a rare neoplasm that originates from the mesothelial cells lining the visceral and parietal pleura. The incidence of malignant pleural mesothelioma in the United States is 15 cases per million; there is a strong correlation with asbestos exposure. Malignant pleural mesothelioma is d

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Sarcomatoid subtype"

Ferzel, Laura Ramos Silva, Kiara de Medeiros Braga Cruz Pessanha, Renata Magliano Marins, Meire Cardoso da Mota Bastos, and Isabelly dos Santos Belo. "Carcinoma metaplásico com diferenciação mesenquimal: relato de caso." In 44° Congresso da SGORJ - XXIII Trocando Ideias. Zeppelini Editorial e Comunicação, 2020. http://dx.doi.org/10.5327/jbg-0368-1416-2020130241.

Повний текст джерела

Анотація:

Introdução: Equivalendo a menos de 5% de todos os cânceres de mama, o carcinoma metaplásico representa um grupo morfologicamente heterogêneo das neoplasias malignas mamárias, que acomete, em sua maioria, mulheres na pós-menopausa. A principal manifestação clínica é nódulo palpável de crescimento progressivo e rápido. Histologicamente, é caracterizado por combinar componente epitelial e componente escamoso ou sarcomatoide. Manifesta-se tipicamente negativo para receptores hormonais e Human Epidermal growth factor Receptor-type 2 (HER2), independentemente do subtipo histológico. Objetivo: Relata

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!